Large Molecule Drugs

Large Molecule Drugs groups companies developing biologics such as antibodies, peptides, nucleic acid therapies, and recombinant proteins. It is a broad category that captures many of the most important platform types in modern biotech.

Why watch Large Molecule Drugs

This page combines a company index, a watch action, and the newest relevant feed items in one place so readers can monitor a biotech theme without scanning each company one by one.

Latest Large Molecule Drugs news

The latest feed items from companies currently grouped under Large Molecule Drugs.

1. 01
   2026-10-01 06:00 EST

   RHHBYRoche presents new data at EURETINA, highlighting Vabysmo’s real-world effectiveness and safety across major retinal conditions

   Source: Roche Holdings AG

2. 02
   2026-10-01 05:00 EST

   RHHBYRoche’s giredestrant combination significantly improved progression-free survival in ER-positive advanced breast cancer in phase III evERA data published in The New England Journal of Medicine

   Source: Roche Holdings AG

3. 03
   2026-09-30 05:00 EST

   RHHBYRoche’s fenebrutinib is the first BTK inhibitor to receive U.S. FDA filing acceptance in both relapsing and primary progressive multiple sclerosis

   Source: Roche Holdings AG

4. 04
   2026-09-29 05:00 EST

   PHARPharming announces CEO transition

   Source: Pharming Group

5. 05
   2026-09-25 14:30 EST

   PHARPharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDS

   Source: Pharming Group

6. 06
   2026-09-23 05:15 EST

   RHHBYPositive interim data shows Roche’s sefaxersen significantly reduces proteinuria in people with IgA nephropathy (IgAN)

   Source: Roche Holdings AG

7. 07
   2026-09-23 05:00 EST

   RHHBYÄnderung im Verwaltungsrat von Roche

   Source: Roche Holdings AG

8. 08
   2026-09-23 05:00 EST

   RHHBYChange in Roche’s Board of Directors

   Source: Roche Holdings AG

9. 09
   2026-09-22 05:00 EST

   RHHBY[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for dual GLP-1/GIP receptor agonist enicepatide in people living with type 2 diabetes and overweight or obesity

   Source: Roche Holdings AG

10. 10
    2026-09-22 05:00 EST

    PHARPharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026

    Source: Pharming Group

11. 11
    2026-09-21 15:45 EST

    RHHBYEuropean Commission approves Roche’s Susvimo® for the treatment of neovascular age-related macular degeneration (nAMD)

    Source: Roche Holdings AG

12. 12
    2026-09-18 10:45 EST

    RHHBYCHMP recommends EU approval of Roche’s Ocrevus for children and adolescents with relapsing multiple sclerosis

    Source: Roche Holdings AG

13. 13
    2026-09-17 18:30 EST

    RHHBYRoche announces grand opening of its Innovation Center Boston to drive advancements in Cardiovascular, Renal and Metabolic diseases

    Source: Roche Holdings AG

14. 14
    2026-09-17 05:00 EST

    RHHBYRoche’s Lunsumio-based regimen significantly improves progression-free survival in follicular lymphoma in phase III CELESTIMO study

    Source: Roche Holdings AG

15. 15
    2026-09-13 00:00 EST

    RHHBYRoche’s collaborator MediLink announces phase III data for Tam-Peli showing significantly improved overall survival in Chinese patient population with relapsed small-cell lung cancer

    Source: Roche Holdings AG

16. 16
    2026-09-11 18:00 EST

    PHARFDA approves Pharming’s Joenja® as first treatment for children with APDS in the U.S.

    Source: Pharming Group

17. 17
    2026-09-10 05:00 EST

    RHHBYU.S. FDA grants Priority Review for Roche’s Enspryng for MOGAD, an autoimmune disease with no approved treatments

    Source: Roche Holdings AG

18. 18
    2026-09-09 06:00 EST

    PHARPharming Group to participate in September investor conferences

    Source: Pharming Group

19. 19
    2026-08-28 07:00 EST

    RHHBYRoche’s Vabysmo demonstrates sustained two-year results in a difficult-to-treat form of neovascular age-related macular degeneration (nAMD)

    Source: Roche Holdings AG

20. 20
    2026-08-20 15:45 EST

    RHHBYRoche’s US subsidiary Genentech announces manufacturing expansion in the United States

    Source: Roche Holdings AG

Companies in Large Molecule Drugs

5 companies tagged with Large Molecule Drugs.

Frequently Asked Questions